{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:53:59Z","timestamp":1791179639909,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune-related cholangitis is a rare immune-related adverse event, and its diagnostic criteria and treatment strategies have not yet been established. Here, we report a case of immune-related cholangitis in which treatment response could be objectively visualized through reassessment of cholangioscopic and histopathological findings before and after treatment. A 79-year-old man with recurrent cutaneous squamous cell carcinoma of the scalp developed high fever and general fatigue after six courses of nivolumab, and laboratory tests revealed marked elevation of hepatobiliary enzymes. Contrast-enhanced computed tomography and endoscopic ultrasonography showed bile duct wall thickening, endoscopic retrograde cholangiopancreatography demonstrated shaggy irregularity in the distal bile duct, and peroral cholangioscopy revealed diffuse surface irregularity and granular changes of the biliary mucosa. Furthermore, cholangioscopy-guided bile duct biopsy demonstrated marked lymphocytic infiltration, particularly infiltration of CD8-positive T cells, leading to a diagnosis of immune-related cholangitis. Prednisolone and ursodeoxycholic acid were initiated, with nivolumab discontinued, after which the clinical symptoms and hepatobiliary enzyme levels gradually improved. Furthermore, on Day 28 after treatment initiation, reassessment by cholangioscopy and bile duct biopsy confirmed improvement in the cholangioscopic findings and reduction of lymphocytic infiltration, particularly CD8-positive T-cell infiltration, on bile duct biopsy. These objective findings supported tapering of steroid therapy. To our knowledge, very few cases have described reassessment of cholangioscopic and histopathological findings before and after treatment in immune-related cholangitis. We suggest that such evaluation may contribute to confirming treatment response and guiding therapeutic strategy in immune-related cholangitis.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1934941","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:32:08Z","timestamp":1791178328000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Cholangioscopic and histopathological findings before and after treatment in immune-related cholangitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yu","family":"Akazawa","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Nosaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouichi","family":"Namikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohtani","sequence":"additional","affiliation":[{"name":"Graduate School of Health and Human Life Sciences, Fukui Prefectural University","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medical Sciences, University of Fukui","place":["Fukui, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1590992","article-title":"Risk factors and long-term prognostic impact of immune-related pancreatic injury in patients receiving immune checkpoint inhibitors","volume":"16","author":"Akazawa","year":"2025","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","journal-title":"World J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2062-3","article-title":"Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report","volume":"67","author":"Kashima","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1055\/a-1899-8619","article-title":"Clinical response in the haustra-like folds observed during peroral cholangioscopy following steroid therapy for immune checkpoint inhibitor-induced cholangitis","volume":"54","author":"Takeda","year":"2022","journal-title":"Endoscopy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1529016","article-title":"Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.021","article-title":"Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab","volume":"107","author":"Noda-Narita","year":"2019","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1981-18","article-title":"Efficacy and safety of chemotherapy following anti-PD-1 antibody therapy for gastric cancer: a case of sclerosing cholangitis","volume":"58","author":"Kono","year":"2019","journal-title":"Intern Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13329","article-title":"Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work","volume":"49","author":"Koya","year":"2019","journal-title":"Hepatol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30189","article-title":"Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis","volume":"69","author":"Ogawa","year":"2019","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2020.101197","article-title":"A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis","volume":"31","author":"Ooi","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000530009","article-title":"Pembrolizumab induced sclerosing cholangitis: why you need a liver biopsy","volume":"16","author":"Liang","year":"2023","journal-title":"Case Rep Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0453-0","article-title":"Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer","volume":"35","author":"Kawakami","year":"2017","journal-title":"Invest New Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1055\/a-0948-1271","article-title":"Peroral cholangioscopy of programmed cell death-1 inhibitor-related sclerosing cholangitis: three case reports","volume":"51","author":"Onoyama","year":"2019","journal-title":"Endoscopy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1055\/a-0640-2392","article-title":"Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer","volume":"50","author":"Kuraoka","year":"2018","journal-title":"Endoscopy"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/a-1756-4388","article-title":"Cholangioscopic appearance of circular folds in immune-related adverse event cholangitis","volume":"54","author":"Tomishima","year":"2022","journal-title":"Endoscopy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12663-023-01976-7","article-title":"A case of cholangitis as a nivolumab-induced immune-related adverse event in a patient with pulmonary metastasis after surgery for oral cancer","volume":"23","author":"Fukuzawa","year":"2024","journal-title":"J Maxillofac Oral Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00250","article-title":"Immune checkpoint inhibitor-induced cholangitis-a three-case series","volume":"5","author":"Gray","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025774","article-title":"A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy","volume":"100","author":"Hirasawa","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.9153","article-title":"A case report of immune checkpoint inhibitor-related myositis and cholangitis induced by pembrolizumab","volume":"12","author":"Yamano","year":"2024","journal-title":"Clin Case Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-020-01287-1","article-title":"A case with life-threatening secondary sclerosing cholangitis caused by nivolumab","volume":"14","author":"Yoshikawa","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.560","article-title":"Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient","volume":"8","author":"Matsumoto","year":"2020","journal-title":"Respirol Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1934941\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:32:09Z","timestamp":1791178329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1934941\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1934941"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1934941","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1934941"}}